References
- Shimada K, Kinoshita T, Naoe T, et al. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895–902.
- Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 2008;26:5134–5136; author reply 5136–5137.
- Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008;26:3189–3195.
- Takahashi M, Bujo H, Jiang M, et al. Enhanced circulating soluble LR11 in patients with coronary organic stenosis. Atherosclerosis 2010;210:581–584.
- Sakai S, Nakaseko C, Takeuchi M, et al. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta 2012;413:1542–1548.
- Kawaguchi T, Ohwada C, Takeuchi M, et al. LR11: a novel biomarker identified in follicular lymphoma. Br J Haematol 2013;163:277–280.
- Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478–485.
- Ohwaki K, Bujo H, Jiang M, et al. A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages. Arterioscler Thromb Vasc Biol 2007;27:1050–1056.
- Weekes CD, Kuszynski CA, Sharp JG. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 2001;40:631–645.
- Kanda M, Suzumiya J, Ohshima K, et al. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. Leuk Lymphoma 1999;34:569–580.
- Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011;155:53–64.
- Kusaba T, Hatta T, Tanda S, et al. Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab. Clin Nephrol 2006;65:222–226.
- Nishii K, Nakaseko C, Jiang M, et al. The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasmino-gen activator receptor (uPAR)-mediated adhesion of immature hematological cells. J Biol Chem 2013;288:11877–11886.
- Matsue K, Asada N, Odawara J, et al. Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 2011;90:417–421.
- Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol 2004;127:173–183.